Business Wire

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

Share

Boehringer Ingelheim stepped up its investments in R&D significantly in 2020 in pursuit of innovative medicines and therapies for diseases for which no satisfactory treatments are available. In particular, efforts to research potential COVID-19 related therapies were accelerated. The company spent 3.7 billion EUR on R&D, 7% more than in the previous year. This represents the highest annual investment in R&D in the 136-year history of the research-driven biopharmaceutical company.

“We started our R&D for potential COVID-19 therapies early in the first quarter of 2020, recognizing the urgent need,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors. “Together with many partners worldwide, this work is ongoing. Our employees have done remarkable work to fight COVID-19, ensure our medicines continued to reach patients and animals, and physicians continued to be supported. Our achievements in 2020 are the result of their effort.”

Building on its vast knowledge in various therapeutic areas, such as respiratory diseases and virology, Boehringer Ingelheim is engaged in several projects aimed at finding medical solutions to treat COVID-19. In December 2020, the company announced together with Cologne University Hospital, the University of Marburg, and the German Center for Infection Research the initiation of Phase I/IIa clinical investigation of BI 767551, the first SARS-CoV-2 neutralizing antibody administrated via inhalation as a potential new therapeutic and prophylactic option to block the virus at the site of infection. Other COVID-19 initiatives include the research and development of SARS-CoV-2 antibodies that can be combined with BI 767551, small molecules to inhibit its replication, and therapy development to prevent microcoagulation (blood clots).

Solid performance despite COVID-19 pandemic
2020 was a good year for Boehringer Ingelheim, although the effects of the COVID-19 pandemic were omnipresent. All of its businesses contributed positively to net sales and operating income. The company recorded net sales of 19.57 billion EUR, a 3% increase compared to the previous year. Foreign currency headwinds had a considerable impact; adjusted for currency effects, net sales rose by 5.6% year on year.

Emphasis on profitable growth and protecting liquidity
Operating income at Group level rose to 4.62 billion EUR (2019: 3.78 billion EUR). One-time gains from divestitures supported the operating income. Income after taxes saw a 12.5% year-on-year increase to 3.06 billion EUR (2019: 2.72 billion EUR). Cash flow from operating activities increased by 619 million EUR to 3.96 billion EUR (2019: 3.34 billion EUR). At the end of 2020, the equity ratio stood at 47% (2019: 44%).

“We are pleased with the results we achieved in 2020, considering the challenging conditions we faced,” said Michael Schmelmer, the Member of the Board of Managing Directors responsible for Finance and Group Functions. “We met our ambitious targets, both in terms of our contribution to the wellbeing of humans, pets and livestock, and our business performance. This allows us to continue to invest even more in R&D, as well as in the long-term opportunities we have identified, most notably in the fields of oncology as well as digital and data technologies.”

Continued high investments in tangible assets
The company invested 1.05 billion EUR (2019: 1.07 billion EUR) in tangible assets in 2020, including the large-scale production facility for biopharmaceutical products (LSCC) in Vienna, Austria, and the new development center for biopharmaceutical medicines (BDC) in Biberach, Germany. Expenditures in tangible assets decreased slightly compared to the all-time high in 2019, due to the partial delay of construction work caused by COVID-19.

Targeted M&A activities round off the portfolio
Boehringer Ingelheim completed several acquisitions in 2020 to selectively expand its portfolio. In July, the company announced the acquisition of Global Stem cell Technology (GST), a Belgian veterinary biotech company. Boehringer Ingelheim acquired GST to develop and produce state-of-the art stem cell products for horses and pets. In September, an equity stake in the China-based New Ruipeng Group, a company that specializes in providing medical care services for pets, was acquired. In December, the company announced the acquisition of all shares of NBE-Therapeutics, a clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform. This acquisition adds another key dimension to Boehringer Ingelheim’s focus on patients with difficult-to-treat solid tumors as part of the company’s comprehensive oncology development portfolio.

Human Pharma – Strong growth across all regions
At 14.42 billion EUR, net sales of human pharmaceuticals grew strongly by 5.8% (year on year and adjusted for currency effects) and accounted for 74% of total net sales. All regions contributed to the strong results in Human Pharma. The United States remains the largest market for Boehringer Ingelheim with the highest regional net sales in the Human Pharma business. Boehringer Ingelheim generated net sales of 5.66 billion EUR in the US, up 3.4% (year on year and adjusted for currency effects). In the EUCAN region (Europe, Canada, Australia, and New Zealand), net sales rose by 6.0% (year on year and adjusted for currency effects) to 4.59 billion EUR. In Emerging Markets, including the People’s Republic of China, Boehringer Ingelheim registered net sales of 2.84 billion EUR, a 10.4% increase (year on year and adjusted for currency effects). In Japan, net sales increased by 6.2% (year on year and adjusted for currency effects) to 1.33 billion EUR.

Medicines for the treatment of cardiovascular and metabolic diseases, as well as respiratory diseases, remain the most important contributors to net sales. JARDIANCE®, a medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes, remains the biggest revenue contributor in Human Pharma, generating net sales of 2.48 billion EUR (2019: 2.15 billion EUR). JARDIANCE® reduces the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease. OFEV® was the company’s second-strongest revenue contributor for the first time, with net sales of 2.06 billion EUR and growth of 41% (year on year and adjusted for currency effects) (2019: 1.49 billion EUR). OFEV® is a medicine for the treatment of patients with idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD) and, in some countries, other chronic fibrosing interstitial lung diseases with a progressive phenotype.

High R&D investment in Human Pharma
R&D investments in the Human Pharma business amounted to 3.28 billion EUR or 22.8% of net sales. There are around 100 projects across all phases of the research process. The goal is for 75% of these projects to be either the first molecule in their active ingredient class or in a new therapeutic area. Over 50% of them have breakthrough potential. The focus of R&D in Human Pharma lies on cardiovascular and metabolic diseases, oncology, respiratory, immunology, diseases of the central nervous system and retinal health.

Animal Health – Strong performance in a highly competitive market
The Animal Health business of Boehringer Ingelheim is one of the largest providers of veterinary vaccines and medicines and has a strong presence in the livestock and companion animal segments. In 2020, the Animal Health business delivered a strong performance in a highly competitive market and grew by 5% (year on year and adjusted for currency effects), withnet sales of 4.12 billion EUR. The swine and pet antiparasitics segments in particular developed successfully and outperformed expectations. In 2020, the decrease in the incidence of African swine fever in China had a rebound effect on the swine segment. As a result, the swine vaccine INGELVAC CIRCOFLEX® registered a strong 14.9% increase in net sales (year on year and adjusted for currency effects) to 264 million EUR (2019: 238 million EUR). The parasiticide NEXGARD® for dogs remained the best-selling product, with growth of 12% (year on year and adjusted for currency effects) and net sales of 804 million EUR.

Biopharmaceutical Contract Manufacturing – One of the leading providers in the industry
Boehringer Ingelheim is one of the leading manufacturers of biopharmaceuticals, both for its own portfolio and for partners in the industry. 60% of the top 20 pharmaceutical companies and innovative biotech firms are clients of Boehringer Ingelheim’s Biopharmaceutical Contract Manufacturing business, known under the brand name Boehringer Ingelheim BioXcellenceTM. The biopharmaceuticals business achieved net sales of 837 million EUR in 2020, up 6.6% (year on year and adjusted for currency effects).

Outlook 2021: Boehringer Ingelheim expects a slight year on year increase in net sales on a comparable basis
The ongoing COVID-19 pandemic and a more challenging industry environment with increasing price pressure in several key markets is expected to have an impact on Boehringer Ingelheim’s results in 2021. Assuming that the approved vaccines and other medicines currently undergoing the approval process help curb the COVID-19 pandemic, the company expects strong general market growth for prescription pharmaceuticals. For 2021, Boehringer Ingelheim expects to achieve a slight year-on-year increase in net sales on a comparable basis.

The 2020 Annual Report can be found here: https://annualreport.boehringer-ingelheim.com/

Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

Learn more at www.boehringer-ingelheim.com.

Please click on the link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/2020-positive-business-momentum-despite-covid-19-impact

Contact information

Boehringer Ingelheim
Corporate Communications and Public Affairs

Mattias Reinig
55216 Ingelheim/Germany
Phone: +49 6132 - 77 18 48 55
Fax: +49 6132 - 77 6601
Email: press@boehringer-ingelheim.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent12.4.2021 17:04:00 CEST | Press release

Merck, a leading science and technology company, today announced key clinical advancements for berzosertib (M6620), an investigational, potent and selective ataxia telangiectasia and Rad3-related (ATR) inhibitor. Berzosertib is the leading asset in the company’s DNA damage response (DDR) inhibitor program and one of the most advanced ATR inhibitors in oncology clinical development industry-wide. Results from a Phase II proof-of-concept study conducted by the US National Cancer Institute (NCI) (NCT02487095)* and published in Cancer Cell showed that berzosertib in combination with the chemotherapy topotecan resulted in an objective response rate (ORR) of 36% among patients with relapsed small cell lung cancer (SCLC), including durable responses among a majority of responding patients with platinum-resistant disease.1 The NCI is also conducting a separate Phase II trial of berzosertib in combination with topotecan versus topotecan monotherapy in SCLC that has relapsed (NCT03896503)* which

Loomis Sayles Welcomes Susan Sieker as Chief Financial Officer12.4.2021 16:15:00 CEST | Press release

Loomis, Sayles & Company, an affiliate of Natixis Investment Managers, announced today that Susan Sieker has joined Loomis Sayles as executive vice president and chief financial officer (CFO). She also joins the Loomis Sayles Board of Directors. Susan reports to Kevin Charleston, chairman and chief executive officer of Loomis Sayles, and will oversee the finance organization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005613/en/ Susan joins Loomis Sayles from Cambridge Associates, where she was the chief financial officer and oversaw financial planning and analysis, treasury, accounting operations, financial reporting, payroll and taxes. Prior to joining Cambridge Associates in 2012, Susan served in a variety of finance and risk leadership roles at Brinker International, including vice president and treasurer, vice president of global infrastructure, vice president of benefits, vice president of business assurance

Alira Health Strengthens Its Growth Strategy With a $35M Funding, Led by Creadev12.4.2021 15:00:00 CEST | Press release

Alira Health (www.alirahealth.com), a leading international advisory firm dedicated to advancing healthcare and life sciences, announced it has closed a $35M equity financing led by Creadev, an evergreen investment company backed by the Mulliez family. This new partnership will help accelerate the firm’s growth strategy, focused on merging pharmaceutical, medical and digital technologies development with medical care through a patient-centric approach. “I would like to thank our team of investors for joining our mission to enable healthcare transformation. Their investment positions us to change the way life sciences advisory services are delivered,” said Gabriele Brambilla, Chief Executive Officer and Co-Founder of Alira Health. “We are building a powerful continuum of services that spans the product and solutions development life cycle, supported by the recent additions of our patient engagement, real-world evidence and advanced analytics practices. This financing allows us to advanc

KD Pharma Acquires Phytoextract and CBD Manufacturing Assets12.4.2021 14:45:00 CEST | Press release

The KD Pharma Group has acquired the manufacturing assets of a Swiss-based cannabinoid manufacturer. The assets give KD Pharma access to technology for producing Active Pharmaceutical Ingredients (APIs) based on phytocannabinoids and other plant extracts. The technology further expands KD’s lipid technology portfolio and can be used in combination with KD’s other fractionation and separation technologies. “KD Pharma is a leader in lipid technology focused primarily on omega-3s, but our technology suite has applications in other lipid sources like cannabinoids,” said Oscar Groet, CEO of the KD Pharma Group. “We have committed to expanding our technology portfolio to develop APIs from cannabinoids and plant extracts,” Groet continued, “and these assets give KD Pharma additional pathways to develop new products for this emerging market.” The KD Pharma Group has also licensed a novel extraction method from Herbolea Biotech S.r.l. and expects to have a complete, licensed cGMP manufacturing

Globality and BT Sourced Announce New Partnership to Unleash the Power of Procurement12.4.2021 14:00:00 CEST | Press release

Through a new partnership with Globality and BT’s new procurement company, BT Sourced, BT launched Globality’s AI-powered Smart Sourcing® Platform to transform how BT employees source and procure services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005173/en/ “BT’s changing and so is procurement. Digitization is the driving force for long-term growth and value to the BT customer and operating model,” said Cyril Pourrat, Chief Procurement Officer, BT. “Partnering with Globality will help us to embrace digital technology and simplify our processes.” “Having immediate access to our current suppliers and Globality’s diverse global network will bring agility and new value to our teams,” added Pourrat. BT now uses Globality’s AI advisor, Glo™, to quickly and easily source the best suppliers for consulting, marketing, IT, HR, legal and other service categories. “BT is revolutionizing the way it sources services in order t

FLIR Wins DARPA Contract Worth Up to $20.5M to Develop Revolutionary New Protective Fabrics for Chem-Bio Defense12.4.2021 14:00:00 CEST | Press release

FLIR Systems, Inc. (NASDAQ: FLIR) announced it has won a contract with the Defense Advanced Research Projects Agency (DARPA) to rapidly develop novel fabrics with embedded catalysts and chemistries that can fight and reduce chemical and biological threats upon contact. The revolutionary fabrics will be incorporated into protective suits and other equipment such as boots, gloves, and eye protection that can be worn by troops on the battlefield, medical experts, healthcare workers, and more. FLIR received $11.2 million in initial funding for the potential five-year effort worth up to $20.5 million, including options. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005140/en/ The Personalized Protective Biosystems (PPB) program will create fabrics with built-in ability to fight chemical and biological agents, from VX to chlorine gas to Ebola virus. The revolutionary fabrics being developed by FLIR Systems will be incorpora

Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis12.4.2021 14:00:00 CEST | Press release

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Vivet Therapeutics (“Vivet”) announced today an agreement whereby Mirum has the exclusive option to develop and subsequently commercialize Vivet’s two proprietary AAV gene therapy programs for progressive familial intrahepatic cholestasis (PFIC), subtypes 3 and 2. The two programs, VTX-803 and VTX-802, are currently being evaluated in preclinical studies by Vivet, a privately-held gene therapy biotechnology company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005354/en/ Under the terms of the agreement, Vivet will continue to advance the preclinical studies for VTX-803 and VTX-802 for PFIC3 and PFIC2, respectively. Mirum has the exclusive option to license the programs after which Mirum would lead the clinical development and any future commercialization of the programs. Until that time, Mirum will provide funding to support the continued research and development costs